Bryan Gant | White & Case LLP International Law Firm, Global Law Practice
Bryan Gant
Bryan Gant

Bryan Gant

Partner, New York

A New York lawyer with experience in antitrust litigation, and particular knowledge of the intersection of antitrust and intellectual property.

Overview

Bryan's practice focuses on complex commercial litigation, and counseling in the areas of antitrust and trade regulation.

A partner in the Firm's Global Antitrust Practice based in New York, he represents clients in the pharmaceutical, financial services and petroleum sectors. Notable recent clients include Pfizer, Actavis, Boehringer Ingelheim, Experian, Novartis, OPEC and Warner Chilcott.

Bryan's knowledge and experience span a wide range of issues, including "reverse payment" settlements of patent disputes, product innovation and product retirement (so-called "product hopping"), price-fixing, fraudulent procurement of patents and other misconduct before the US Patent & Trademark Office, sham litigation, sham petitioning of the FDA, product bundling, and other antitrust theories.

Bryan is a regular contributor to Antitrust Law Developments, and a member of the Antitrust Section of the American Bar Association.

Bars and Courts

  • New York State Bar
  • US District Court for the Eastern District of New York
  • US District Court for the Southern District of New York
  • US Court of Appeals for the Second Circuit
  • US Court of Appeals for the Eighth Circuit

Education

  • JD, University of Chicago Law School
  • BA, Winthrop University

Languages

  • English

Experience

'In re Lipitor Antitrust Litigation,' ongoing

Bryan is representing Pfizer in class action litigation accusing the company of delaying entry of generic competition to Lipitor, the largest-selling pharmaceutical of all time. The asserted claims include misconduct before the US Patent and Trademark Office, and an alleged "reverse payment" patent settlement. White & Case secured the dismissal of all claims in the case.

'In re Effexor Antitrust Litigation,' ongoing

Bryan is representing Wyeth Pharmaceuticals in class action litigation alleging delayed generic competition to Effexor XR, a blockbuster antidepressant medication. Claims include misconduct before the US Patent and Trademark Office, and an alleged "reverse payment" patent settlement. White & Case secured the dismissal of all reverse payment settlement claims in the case, which is currently on appeal.

'In re Loestrin Antitrust Litigation,' ongoing

Bryan is representing Warner Chilcott (now owned by Actavis) in class action litigation alleging a reverse payment settlement regarding the oral contraceptive Loestrin. In 2014, White & Case obtained the dismissal of all claims in the case.

'In re Aggrenox Antitrust Litigation,' ongoing

Bryan is representing Boehringer Ingelheim in class action litigation arising from a claimed "reverse payment" patent settlement, which allegedly delayed generic competition to Aggrenox.

'Fair Isaac Corporation v. Equifax, et al.,' 2011

Bryan secured summary judgment dismissing antitrust claims lodged by Fair Isaac Corporation against Experian, stemming from the formation of a competing consumer credit scoring service by the three major US credit bureaus. White & Case subsequently achieved a favorable jury verdict for Experian in trademark claims asserted by Fair Isaac. The Eighth Circuit Court of Appeals affirmed both the antitrust dismissal and the jury's verdict.

'Rx USA Antitrust Litigation,' 2010

Acting on behalf of Novartis Pharmaceutical Corporation, Bryan secured the Second Circuit Court of Appeals' affirmance of the dismissal of an antitrust action accusing 16 major international pharmaceutical companies and the largest US pharmaceutical wholesalers of a group boycott, in violation of the antitrust laws.

Publications

  • European Union Blocks Merger of NYSE Euronext and Deutsche Bӧrse AG, The Exchange newsletter, published by the Insurance and Financial Services Committee of the ABA Antitrust Section, Fall 2012, (co-author with S. Lynn Diamond)

Awards & Recognition

Rising Star, Law 360, 2015

Antitrust